$CURR is looking very good for 2023. The upcoming
Post# of 102052
https://finance.yahoo.com/news/cure-pharmaceu...00414.html
From the Q3 results:
*Revenue in the third quarter surged 32.1% year-over-year and 58.9% sequentially from Q2 2022 to $1.8 million with further increases expected in Q4.
*Gross margins for the third quarter improved by 123 basis points to 80.0% in 2022 compared to the same period in 2021 with expectations of continuing high margin sales with our new marketing initiatives.
*SG&A expenses (excluding non-cash charges) for the third quarter decreased by $0.1 million in 2022 compared to 2021.
*Cost reductions and operating leverage helped narrow operating loss (excluding non-cash charges) by $0.6 million in 2022 versus 2021 despite enhanced marketing investment.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)